Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $23.6300 (-3.25%) ($23.6300 - $23.6300) on Sat. Aug. 7, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.99% (three month average) | RSI | 21 | Latest Price | $23.6300(-3.25%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -8.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -18.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) (0%) (0%) (0%) (0%) (0%) | Factors Impacting TGTX price | TGTX will decline at least -1.995% in a week (0% probabilities). (0%) (0%) (0%) (0%) (0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.995% (StdDev 3.99%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $1.26(-94.67%) | Resistance Level | $33.67 | 5 Day Moving Average | $24.97(-5.37%) | 10 Day Moving Average | $29.84(-20.81%) | 20 Day Moving Average | $33.67(-29.82%) | To recent high | -41.6% | To recent low | 0% | Market Cap | $N/A | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |